34 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in May 2034. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
May 2034
Next term end
13
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends May 2034 · Low confidence
Also notable
Ends Sep 2036 · Medium confidence
Also notable
Ends Nov 2035 · High confidence
Also notable
Ends Jun 2038 · High confidence
Also notable
Ends Jan 2038 · High confidence
Also notable
Ends Jan 2040 · Medium confidence
Also notable
Ends Jun 2037 · High confidence
Also notable
Ends May 2040 · High confidence
Compositions and Methods for Growth Factor Modulation
US 10,597,443
Cited by 41 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2034. A terminal disclaimer caps this term to an earlier patent's.
Methods for Inhibiting Myostatin Activation by Administering Anti-Pro/Latent Myostatin Antibodies
US 10,287,345
Cited by 20 later US patents, top 25% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2036.
Anti-Pro/Latent-Myostatin Antibodies and Uses Thereof
US 10,307,480
Cited by 18 later US patents, top 25% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2035.
TGFbeta1-BINDING IMMUNOGLOBULINS AND USE THEREOF
US 11,643,459
Cited by 6 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2038.
Compositions and Methods for Making and Using Anti-Myostatin Antibodies
US 11,155,611
Granted 2021. Computed term ends 2038.
LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOF
US 11,214,614
A family of 5 related applications built on the 2022 grant. Protection runs to 2040.
Use of Myostatin Inhibitors and Combination Therapies
US 10,946,036
Granted 2021. Computed term ends 2037.
Isoform-Selective TGFB1 Inhibitors and Use Thereof
US 11,130,803
Granted 2021. Computed term ends 2040.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due May 28, 2027The maintenance fee for Compositions and Methods for Growth Factor Modulation (US 11,827,698) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
- 2 fees due Sep 12 to 24, 2027 · next Sep 12
Recent changes
- Sep 18Assignment recorded on 1 record: Chapron, Christopher and 9 others to Scholar Rock, Inc. Recorded Sep 18, 2026, executed Nov 22, 2023. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76066, frame 860.
- 1 of the patents on this record was granted since Aug 22, 2026
What they patent
The largest of its 13 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,399,676 | Compositions and Methods for Growth Factor Modulation In force · Medium confidence | In force | Medium confidence | |
| US 9,573,995 | Compositions and Methods for Growth Factor Modulation In force · Medium confidence | In force | Medium confidence | |
| US 9,580,500 | Compositions and Methods for Growth Factor Modulation In force · Medium confidence | In force | Medium confidence | |
| US 9,758,576 | Compositions and Methods for Growth Factor Modulation In force · Low confidence | In force | Low confidence | |
| US 9,758,577 | Compositions and Methods for Growth Factor Modulation In force · Low confidence | In force | Low confidence | |
| US 10,597,443 | Compositions and Methods for Growth Factor Modulation In force · Low confidence | In force | Low confidence | |
| US 10,981,981 | Compositions and Methods for Growth Factor Modulation In force · Medium confidence | In force | Medium confidence | |
| US 11,827,698 | Compositions and Methods for Growth Factor Modulation In force · Low confidence | In force | Low confidence | |
| US 12,454,570 | Compositions and Methods for Growth Factor Modulation In force · Low confidence | In force | Low confidence | |
| US 12,577,296 | Compositions and Methods for Growth Factor Modulation In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 34: 21 applications pending · 15 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.